PAs and NPs of the Florida Keys

Exploring Novel and Emerging Prophylactic Therapies for Hereditary Angioedema

CE Information
0.75 CME credits
Completion Time
45 minutes
Available Until
August 29, 2024
Posted By
Prime CE
Prime CE Prime CE
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.

Overview

Specialties
Adult and Family
Subspecialties
Allergy/Immunology
Clinical Topics
Allergies and Autoimmune Disorders

Intended Audience: Allergists/immunologists, emergency medicine physicians, dermatologists, primary care physicians, pediatricians, geneticists, and their care teams (NPs, PAs, nurses, pharmacists)

Join two expert faculty in this engaging evidence-based discussion focused on the prophylactic treatment of hereditary angioedema (HAE).

View a custom whiteboard animation to gain a deeper understanding of the pathophysiology of the disease and targets of novel and emerging prophylactic therapies.

The latest clinical data for these agents, as well as strategies for individualizing management plans, will also be explored.

Learning Objectives

  • Differentiate the inflammatory pathways and mediators involved in the pathogenesis of HAE
  • Evaluate new and emerging long-term prophylactic therapies for HAE based on their mechanisms of action and routes of administration, as well as the latest clinical efficacy and safety data
  • Develop individualized management plans for patients with HAE that integrate patient- and disease-specific factors into personalized treatment decisions for prophylaxis

Speakers

Marc Riedl
Marc Riedl MD, MS

Professor
Clinical Director
US HAEA Angioedema Center
University of California, San Diego
La Jolla, California

Raffi Tachdjian
Raffi Tachdjian MD, MPH

Associate Professor
Allergy and Clinical Immunology
UCLA School of Medicine

CE Information

This activity offers 0.75 CME credits to attendees.

Accredited by AANP.

Please click here for all CE Details & Instructions.

Disclosures

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

  • Marc Riedl, MD, MS (Speaker)
    Consultant  Astria, Biocryst, Biomarin, CSL Behring, Cycle Pharma, Grifols, Kalvista, Pfizer, Pharming, Pharvaris, Sanofi-Regenero, Takeda
    Grants / Research Support  Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Pharvaris, Takeda
    Speakers Bureau or other Promotional Education  Grifols, Pharming, Takeda
    The relationships reported above are related to the following therapeutic area: Allergy, Immunology, Inflammation
  • Raffi Tachdjian, MD, MPH (Speaker)
    Advisory Board or Panel  Astria, CSL Behring, Ionis, Kalvista, Pharming, Takeda
    Consultant  Ionis, Kalvista
    Grants / Research Support  Astria, CSL Behring, Ionis, Kalvista, Pharming, Pharvaris, Takeda
    Speakers Bureau or other Promotional Education  CSL Behring, Pharming, Takeda
    The relationships reported above are related to the following therapeutic area: Allergy, Immunology, Inflammation
  • Kristi Kay Orbaugh, RN, MSN, RNP, AOCN (Planner)
    Speakers Bureau or other Promotional Education  AstraZeneca, Bristol-Myers Squibb, CTI, DSI, Dova, Eli Lilly and Company, Gilead Sciences
    The relationships reported above are related to the following therapeutic area: Oncology

The following individuals have no relevant financial relationships with ineligible companies to disclose:

  • Jason Welch, MD (Reviewer)
  • Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.


Ready to start this activity?

Login required. You will be redirected to an external website to register for and complete this activity.

Log in and start activity